AlphaRx Presents Positive Data From Preclinical Studies of Cystic Fibrosis Drug

AlphaRx has announced positive pre-clinical data on Zysolin, a Tobramycin compound encapsulated in the company’s nano drug delivery platform intended for the treatment of cystic fibrosis and an adjunctive treatment of Gram-negative pneumonia in intubated and mechanically-ventilated patients.

In the recent animal study, the therapeutic efficacy of Zysolin was investigated in a mouse model of Pseudomonas aeruginosa pneumonia. In this acute model, pneumonia developed rapidly, resulting in a high mortality rate, no mice survived after 24 hours of infection without treatment.

Mice treated with Zysolin showed significantly better efficacy than Tobramycin, achieving 60% survival rate compared to 40% in the Tobramycin treatment group. An increase of survival by 50% or more, relative to vehicle control, indicates significant anti-microbial effect. The Tobramycin treatment group did not meet the study’s end point.